Tradestie Institutional Equity Comparison Engine

MRNA vs GILD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

GILD Overall Edge

GILD Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Gilead Sciences Inc (GILD) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus GILD at 16.4x Forward P/E and 38.2% operating margin (+6.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against GILD sits in SURGE (61st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GILD
MRNA 23.0x vs GILD 16.4x Fwd P/E
Growth & Margin Winner GILD
Op Margin -80.8% vs 38.2% ยท YoY +29.2% vs +6.8%
Momentum & Technical Winner MRNA
1Y +706.5% vs +29.9% ยท 52W Pos 67% vs 83%
Options & Structure Winner GILD
CONSOLIDATION (52nd %ile IV) vs SURGE (61st %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
GILD NASDAQ
Gilead Sciences Inc
Biological Products, (No Disgnostic Substances)
$166.43
-0.06% 1D
Market Cap $206.6B
1M Return +5.88%
1Y Return +29.95%
Forward P/E 16.4x
Unified AI Score
42.9 / 100 HOLD
Tech 32.0 Fund 49.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% GILD +29.95% Spread: +676.5 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue GILD Revenue MRNA Op. Margin GILD Op. Margin Margin Edge
FY2018 $140M $22.1B -306.0% 37.1% GILD
FY2019 $60M $22.4B -906.8% 19.1% GILD
FY2020 $800M $24.7B -95.0% 16.5% GILD
FY2021 $18.5B $27.3B 72.0% 36.3% MRNA
FY2022 $19.3B $27.3B 48.9% 26.9% MRNA
FY2023 $6.85B $27.1B -61.9% 28.0% GILD
FY2024 $3.24B $28.8B -121.9% 5.8% GILD
FY2025 $1.94B $29.4B -158.1% 34.0% GILD

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (1) vs GILD (9)
Institutional Metric MRNA GILD Criterion Row Winner
Market Capitalization Scale $80.7B $206.6B Larger Scale GILD
Trailing P/E Ratio Valuation 23.0x 16.8x Lower Multiple GILD
Forward P/E Ratio Valuation 23.0x 16.4x Lower Multiple GILD
Revenue Growth (YoY) Growth +29.2% +6.8% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 38.2% Higher Margin GILD
Net Profit Margin Profitability -110.5% -12.5% Higher Margin GILD
Return on Equity (ROE) Capital Efficiency -34.5% -22.4% Higher ROE GILD
52-Week Range Position Momentum 67% ($22โ€“$281) 83% ($117โ€“$177) Stronger Trend GILD
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.31ฮฒ ยท 30% Vol Lower Realized Risk GILD
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite GILD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs GILD Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GILD SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 61st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live GILD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor GILD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.